On November 20, GIANT BIOGENE fell 4.03% in Regular Trading, trading at HK$18.04, with turnover of HK$13.74 million.
The move was accompanied by a fresh broker update: HSBC maintained a Hold rating but cut its target price to HK$20.7 from HK$28.1 and lowered its revenue and net profit forecasts for the next three fiscal years.
HSBC said the main reason was that the Double 11 GMV growth of the companys core brand Comfy only reached 5% year over year, missing expectations for a stronger recovery despite a low base in the prior-year period. Based on a weaker growth outlook, HSBC reduced revenue forecasts for the coming three years by 5%, 8%, and 11%, and cut net profit forecasts by 3.3%, 2.0%, and 2.6%.
Recent sentiment had already been pressured by an earlier target price cut from Citi, a 30-day negative catalyst watch, and the stocks removal from the MSCI China Index, adding to near-term overhang.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments